(Q39018465)

8 September 2017

1 reference

14 July 2021

1 reference

PubMed publication ID

27881735

title

Therapy-activated stromal cells can dictate tumor fate (English)

1 reference

chemokine receptor family

8 September 2017

1 reference

18 December 2019

1 reference

8 February 2021

1 reference

14 July 2021

Robert S Kerbel

1

1 reference

8 September 2017

Yuval Shaked

series ordinal

2

1 reference

8 September 2017

language of work or name

English

0 references

publication date

23 November 2016

1 reference

Journal of Experimental Medicine

8 September 2017

12 December 2016

6 references

3 April 2019

31 July 2019

15 December 2019

18 December 2019

8 February 2021

14 July 2021

7 references

8 September 2017

3 April 2019

31 July 2019

15 December 2019

18 December 2019

8 February 2021

14 July 2021

213

1 reference

8 September 2017

13

1 reference

8 September 2017

2831-2833

1 reference

Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells.

8 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5154951

Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5154951

Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5154951

Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5154951

Clinical overview of metronomic chemotherapy in breast cancer.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5154951

Metronomic chemotherapy: new rationale for new directions

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5154951

Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5154951

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5154951

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5154951

Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5154951

Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5154951

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.

21 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1084%2FJEM.20161845

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1084%2FJEM.20161845

Maintenance treatment in metastatic colorectal cancer

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27881735

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Gastrointestinal cancer: Rationale for metronomic chemotherapy in phase III trials

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27881735

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1084/JEM.20161845

1 reference

8 September 2017

1 reference

8 September 2017

PubMed publication ID

27881735

1 reference